Department of Neurology (and Sleep Center), Changhua Christian Hospital Yun Lin Branch, Taiwan.
Kaohsiung J Med Sci. 2010 Aug;26(8):422-7. doi: 10.1016/S1607-551X(10)70068-1.
This is the first report describing the efficacy of modafinil therapy for narcolepsy in patients in Taiwan. The purpose of this study was to compare the objective Multiple Sleep Latency Test (MSLT) and the subjective Epworth Sleepiness Scale (ESS) for evaluating the efficacy of modafinil in treating excessive daytime sleepiness in patients with narcolepsy in Taiwan. Ten consecutive patients with narcolepsy-with-cataplexy who were treated with 200 mg/day modafinil for more than 6 months at our sleep center between January 2003 and December 2007 were included in this study. This comparative study was prompted by the requirement of the Bureau of National Health Insurance in Taiwan that modafinil users need to be followed up with MSLTs every 6-12 months. The mean age at onset of narcolepsy onset in these 10 patients was 11.8 +/- 3.3 years, and eight (80%) were male. We compared the differences in MSLT and ESS between baseline and follow-up at 6-12 months after starting modafinil therapy using paired t tests. ESS scores (p < 0.001) were considerably more sensitive than MSLT scores (p < 0.05) in documenting efficacy of modafinil and that the improvements in MSLT scores were minimal and remained in the pathologically sleepy range. These findings suggest that the ESS is a more sensitive and clinically meaningful tool to evaluate the efficacy of modafinil in narcolepsy.
这是第一篇描述莫达非尼治疗台湾地区嗜睡症患者疗效的报告。本研究的目的是比较客观的多次睡眠潜伏期试验(MSLT)和主观嗜睡量表(ESS),以评估莫达非尼治疗台湾地区嗜睡症患者日间过度嗜睡的疗效。2003 年 1 月至 2007 年 12 月期间,我们睡眠中心连续收治了 10 例接受 200mg/天莫达非尼治疗 6 个月以上的嗜睡症伴猝倒患者。本研究是由台湾地区国民健康保险局要求莫达非尼使用者每 6-12 个月进行 MSLT 随访而促成的。这 10 例患者的嗜睡症发病年龄平均为 11.8 +/- 3.3 岁,8 例(80%)为男性。我们采用配对 t 检验比较了莫达非尼治疗开始后 6-12 个月 MSLT 和 ESS 基线与随访之间的差异。ESS 评分(p < 0.001)比 MSLT 评分(p < 0.05)更能敏感地记录莫达非尼的疗效,且 MSLT 评分的改善甚微,仍处于病理性嗜睡范围内。这些发现表明 ESS 是评估莫达非尼治疗嗜睡症疗效的一种更敏感、更有临床意义的工具。